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Huntington’s disease (HD), MIM 143100, is a dominantly inherited
progressive neurodegenerative disorder characterised by motor,
behavioural and cognitive dysfunction, caused by an expanded
CAG repeat region in exon 1 of the HTT gene. This mutation
results in the presence of an abnormally long polyglutamine tract
in the encoded protein, huntingtin. Research into this disorder has
conventionally focused on neurological symptoms and brain
pathology, particularly neurodegeneration in the basal ganglia and
cerebral cortex. Mutant huntingtin is, however, ubiquitously
expressed throughout the body. Contrary to earlier thinking, HD is
also associated with abnormalities in peripheral tissues. Due to
obvious problems in obtaining brain tissue, these peripheral tissues
can be studied to elucidate pathogenetic mechanism (still not well
understood) of the disease as well as identifying disease biomarkers.
Peripheral tissue dermal ﬁbroblasts, which have the same ecto-
dermal origin as CNS cells, may represent an alternative source for
biological studies. Furthermore, contrary to peripheral blood cells,
this cell type is not directly exposed to drugs. We performed gene
expression proﬁle analysis of human ﬁbroblasts obtained from HD
patients and healthy controls matched by age and sex. The study
was performed using the whole genome Affymetrix HG U133 plus
2.0 arrays. Preliminary data obtained indicate that 451 genes are
upregulated twofold or greater in patients compared with controls
while 17 are downregulated. This study allowed us to evidence the
modulation at the transcriptional level of a discrete number of
genes relevant in biological processes which are altered in the
diseasedprocesses such as transcription and its regulation, apop-
tosis, regulation of actin cytoskeleton, inositol phosphate meta-
bolism and vesicle mediated transport. We plan to extend this type
of analysis to a larger number of cases and controls and to conﬁrm
the differential expression of interesting genes both at the RNA and
protein levels. The data generated by this study could provide novel
clues on the Huntington pathogenesis and lead to the identiﬁcation
of a set of mRNAs that appear to be useful as biomarkers of the
disease.
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Background A potential biomarker role for magnetic resonance
spectroscopy (MRS) in Huntington’s disease (HD) is unclear due to
conﬂicting reports in the literature.
Aim To investigate MRS as an HD biomarker through cross
sectional and longitudinal examinations in a TRACK-HD study
cohort.
Methods Cross sectional MRS of the left putamen (at 3T ﬁeld
strength) was performed in the University of British Columbia
TRACK-HD study cohort. 84 individuals (30 controls (C), 25 pre-
HD (P), 29 early HD (E)) were scanned at baseline. 78 individuals
(29 (C), 26 (P) and 23 (E)) underwent repeat MRS examination at
1 year. Metabolites of interest were total N-acetyl aspartate
(tNAA) and myo-inositol (MI); markers of neuronal health and
gliosis.
Results Baseline tNAA concentrations in early HD were lower than
in controls (mean (SD) 8.6 (0.7) mM (C) vs 7.3 (1.2) mM (E);
p<0.001). MI was higher in early HD compared with controls (6.0
(2.6) mM (E) vs 4.3 (1.4) mM (C); p<0.005). After 1 year, MI
concentrations remained 40% higher in early HD (6.0 (2.7) mM (E)
vs 4.2 (1.1) mM (C); p<0.01). tNAA was still lower in early HD
(p<0.001) but also in pre-HD (p<0.05) than controls (7.4 (0.9) mM
(E) vs 8.2 (0.8) mM (P) vs 8.7 (0.6) mM (C)). Neither tNAA nor MI
exhibited longitudinal change in any group. A novel observation was
that of 30% increases in spectral linewidth in early HD at both time
points (p<0.01).
Conclusions Our data support patterns of higher MI levels and lower
tNAA in early HD. The pattern of lower tNAA may begin in
premanifest HD. The lack of longitudinal metabolite change is not
unusual over such a short duration of follow-up. We also identiﬁed
for the ﬁrst time, consistent increases in MRS spectral linewidth in
early HD.
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Background Cultured skin ﬁbroblasts from HD patients seem to be
an attractive model for in vitro studies of molecular pathology in
HD, and in the hunt for HD biomarkers, as sampling is minimally
invasive and the effect of the mutation can be studied in the correct
genetic background.
Aims Here we discuss results gathered from the literature together
with some of our own unpublished results on HD patient ﬁbro-
blasts.
Outcome Although HD primary ﬁbroblast cultures have been
established and studied for a long time, results revealing charac-
teristic phenotypic traits of this cell type are sparse. Many inves-
tigations have focused on growth characteristics but no conclusion
could be drawn just as studies of cellular morphology so far have
yielded somewhat confounding results. There have been multiple
explanations suggested, including variations in growth character-
istics of individual cell lines, which are also known from normal
ﬁbroblast cultures, and differences in culture conditions like the
use of different culture media, concentration of serum, addition of
antibiotics, surface of culture disc, etc, conditions which make it
difﬁcult to compare results obtained from different experimental
set-ups. Recently, examples of functional deﬁcits have been found
in HD ﬁbroblasts including vesicular trafﬁcking, lipid metabolism
and proteasome inhibition as well as growth factor and enzyme
activity changes. Future investigations are needed to reveal
the pathways involved and to show if they relate to changes in
CNS.
Conclusion Our considerations are useful for planning collection of
skin biopsies and multicentre studies on cultured ﬁbroblasts.
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